HRP20141035T1 - Sastavi i metode za lijeäśenje multiple skleroze - Google Patents
Sastavi i metode za lijeäśenje multiple skleroze Download PDFInfo
- Publication number
- HRP20141035T1 HRP20141035T1 HRP20141035AT HRP20141035T HRP20141035T1 HR P20141035 T1 HRP20141035 T1 HR P20141035T1 HR P20141035A T HRP20141035A T HR P20141035AT HR P20141035 T HRP20141035 T HR P20141035T HR P20141035 T1 HRP20141035 T1 HR P20141035T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- multiple sclerosis
- use according
- treatment
- administration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 19
- 201000006417 multiple sclerosis Diseases 0.000 title claims 9
- 239000013543 active substance Substances 0.000 claims 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 2
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Claims (12)
1. Sastav obuhvaća muramil dipeptid poprečno povezan u mikročesticu za uporabu u liječenju multiple skleroze.
2. Sastav obuhvaća muramil dipeptid poprečno povezan u mikročesticu za uporabu u liječenju simptoma multiple skleroze u sublekta s multiplom sklerozom.
3. Sastav za uporabu u skladu s patentnim zahtjevom 1, pri čemu sastav treba primijeniti s jednim ili više drugih aktivnih agenasa učinkovitih u liječenju multiple skleroze.
4. Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu je tip multiple skleroze koju treba liječiti odabran između progresivne i relapsirajuće-popuštajuće multiple skleroze.
5. Sastav za uporabu u skladu s patentnim zahtjevom 4, pri čemu je progresivna multipla skleroza odabrana između primarne progresivne, sekundarne progresivne ili kronične progresivne multiple skleroze.
6. Sastav za uporabu u skladu s patentnim zahtjevom 4, pri čemu je tip multiple skleroze koju treba liječiti relapsirajuće-popuštajuća multipla skleroza.
7. Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je sastav za davanje subjektu intramuskularno, intraperitonealno, intravenski, subkutano, rektalno, nazalno, oralno, intragastrično i plućno.
8. Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je sastav za davanje subjektu infuzijom ili injekcijom.
9. Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, pri čemu je sastav za davanje subjektu u dozi raspona od 50 µg do 1500 µg.
10. Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 9, pri čemu je sastav za davanje subjektu dnevno, tjedno, dvotjedno ili mjesečno.
11. Sastav za uporabu u skladu s patentnim zahtjevom 3, pri čemu je jedan ili više aktivnih agenasa učinkovit u liječenju multiple skleroze za davanje istodobno ili u slijedu, bilo kojim redom, sa sastavom.
12. Sastav za uporabu u skladu s patentnim zahtjevom 3, pri čemu je jedan ili više aktivnih agenasa učinkovit u liječenju multiple skleroze odabran između kortikosteroida, interferona, glatiramer acetata, mitoksantrona, protutijela ili njihovih kombinacija.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141035T1 true HRP20141035T1 (hr) | 2014-12-19 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141035AT HRP20141035T1 (hr) | 2009-06-16 | 2014-10-27 | Sastavi i metode za lijeäśenje multiple skleroze |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (hr) |
| EP (1) | EP2442832B1 (hr) |
| JP (1) | JP5646617B2 (hr) |
| CN (1) | CN102458476B (hr) |
| AU (1) | AU2010260585B2 (hr) |
| BR (1) | BRPI1009606A2 (hr) |
| CA (1) | CA2688766C (hr) |
| CY (1) | CY1115714T1 (hr) |
| DK (1) | DK2442832T3 (hr) |
| ES (1) | ES2521565T3 (hr) |
| HK (1) | HK1167101A1 (hr) |
| HR (1) | HRP20141035T1 (hr) |
| IL (1) | IL216993A (hr) |
| IN (1) | IN2012DN00167A (hr) |
| MX (1) | MX2011013661A (hr) |
| NZ (1) | NZ577731A (hr) |
| PL (1) | PL2442832T3 (hr) |
| PT (1) | PT2442832E (hr) |
| SI (1) | SI2442832T1 (hr) |
| SM (1) | SMT201400165B (hr) |
| WO (1) | WO2010147484A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5569944B2 (ja) * | 2008-04-01 | 2014-08-13 | イネイト・イムノセラピューティクス・リミテッド | 抗感染薬およびその使用 |
| LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| KR20170041116A (ko) * | 2015-10-06 | 2017-04-14 | 이네이트 이뮤노테라퓨틱스 리미티드 | 신경계의 보호 및/또는 복구용 조성물 및 방법 |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019218079A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| US20210169904A1 (en) * | 2018-07-03 | 2021-06-10 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU732809B2 (en) * | 1996-10-10 | 2001-05-03 | Innate Immunotherapeutics Limited | Compositions and methods for treating viral infections |
| AU2005259726A1 (en) * | 2004-07-01 | 2006-01-12 | Kobenhavns Universitet | Method for multiple sclerosis treatment and prophylaxis by treatment of Leptospira infection |
| WO2008070564A1 (en) | 2006-12-01 | 2008-06-12 | The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services | Uses of muramyl dipeptide (mdp) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en active Application Filing
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2012
- 2012-08-10 HK HK12107888.6A patent/HK1167101A1/xx not_active IP Right Cessation
-
2014
- 2014-10-27 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2442832T3 (da) | 2014-11-10 |
| CY1115714T1 (el) | 2017-01-25 |
| MX2011013661A (es) | 2012-05-22 |
| AU2010260585B2 (en) | 2013-02-21 |
| US20100317589A1 (en) | 2010-12-16 |
| CN102458476A (zh) | 2012-05-16 |
| AU2010260585A8 (en) | 2012-06-14 |
| SI2442832T1 (sl) | 2014-12-31 |
| JP5646617B2 (ja) | 2014-12-24 |
| PL2442832T3 (pl) | 2015-01-30 |
| HK1167101A1 (en) | 2013-02-01 |
| WO2010147484A8 (en) | 2012-07-19 |
| EP2442832A1 (en) | 2012-04-25 |
| WO2010147484A1 (en) | 2010-12-23 |
| CN102458476B (zh) | 2014-08-20 |
| IL216993A0 (en) | 2012-02-29 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| JP2012530132A (ja) | 2012-11-29 |
| EP2442832A4 (en) | 2013-07-03 |
| CA2688766C (en) | 2015-06-30 |
| PT2442832E (pt) | 2014-11-11 |
| AU2010260585A1 (en) | 2012-01-19 |
| NZ577731A (en) | 2010-08-27 |
| ES2521565T3 (es) | 2014-11-12 |
| EP2442832B1 (en) | 2014-08-06 |
| IN2012DN00167A (hr) | 2015-04-17 |
| SMT201400165B (it) | 2015-01-15 |
| US8389479B2 (en) | 2013-03-05 |
| CA2688766A1 (en) | 2010-12-16 |
| IL216993A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141035T1 (hr) | Sastavi i metode za lijeäśenje multiple skleroze | |
| JP2007262090A5 (hr) | ||
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| JP2013533858A5 (hr) | ||
| JP2018515557A5 (hr) | ||
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| HRP20191383T1 (hr) | Liječenje subpopulacija oboljelih od alzeimerove bolesti pomoću prikupljenog imunoglobulina g | |
| MA43283B1 (fr) | Composition pour le traitement du cancer | |
| JP2013507439A5 (hr) | ||
| RU2021106383A (ru) | Состав для ингибирования образования агонистов 5-ht2b и способы его применения | |
| MX349162B (es) | Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo. | |
| RS52885B (en) | LOW-FREQUENCY GLATIRAMER ACETATOM THERAPY | |
| JP2012517478A5 (hr) | ||
| JP2008510714A5 (hr) | ||
| JP2015529225A5 (hr) | ||
| JP2013521231A5 (hr) | ||
| JP2014527040A5 (hr) | ||
| JP2019529541A5 (hr) | ||
| MX2012008652A (es) | Terapias para tratar infeccion por virus de hepatitis c. | |
| HRP20160328T1 (hr) | Tritokvalin za uporabu u liječenju cistične fibroze | |
| JP2016517401A5 (hr) | ||
| JP2014529399A5 (hr) | ||
| JP2009501230A5 (hr) | ||
| JP2013526535A5 (hr) | ||
| HRP20231652T1 (hr) | Peptidi za primjenu u liječenju oralnog mukozitisa |